Work

Supplementary Tables 1 and 2 from Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table 1: A standard 3 + 3 dose escalation design (19) was used to investigate 3 dose levels of CD-NSCs and 5-FC. Supplementary Table 2: Characteristics of the 15 patients who received study treatment.

DOI: 10.1158/1078-0432.22462329.v1

Authors: Jana Portnow, Timothy W. Synold, Behnam Badie, Revathiswari Tirughana, Simon F. Lacey, Massimo D'Apuzzo, Marianne Z. Metz, Joseph Najbauer, Victoria Bedell, Tien Vo, Margarita Gutova, Paul Frankel, Mike Chen, Karen S. Aboody

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361920705

Cites:

Cited by:

Related to: 10